The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways

Brain Research Bulletin
Gayani R WeerasingheFrancesca Bosetti

Abstract

The mood-stabilizer lithium, when chronically administered to rats at therapeutic concentrations, has been shown to downregulate brain arachidonic acid (AA) turnover and total phospholipase A2 (PLA2) activity, as well as protein and mRNA levels of cytosolic cPLA2. These effects are accompanied by a decrease in cyclooxygenase (COX)-2 protein level, COX activity, and brain prostaglandin E2 (PGE2) concentration. The involvement of Ca2+-dependent secretory PLA2 (sPLA2) in the mechanism of action of lithium has not been investigated. The purpose of this study was to examine, whether the effect of lithium is selectively directed to cPLA2 or it also affects sPLA2 protein and enzyme activity and whether other AA metabolizing enzymes (5-lipoxygenase and cytochrome P450 epoxygenase) were also altered. Furthermore, to determine if the reduction of brain PGE2 concentration was due only to downregulation of COX-2 protein or if it also involves the terminal PGE synthase, we determined brain microsomal PGE synthase protein level. Male Fischer-344 rats were fed lithium chloride for 6 weeks, whereas, control rats were fed lithium-free chow under parallel conditions. We found that chronic lithium did not significantly change sPLA2 activity or pr...Continue Reading

References

Dec 20, 1996·Neuroscience Letters·M C ChangS I Rapoport
Jan 10, 2004·Journal of Neurochemistry·Francesca Bosetti, Gayani R Weerasinghe

❮ Previous
Next ❯

Citations

Feb 19, 2005·Psychopharmacology·Sandra GhelardoniFrancesca Bosetti
Nov 18, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mireille BasselinStanley I Rapoport
Nov 12, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Sumit SethiElisa Brietzke
Dec 20, 2011·Brain Research Bulletin·Mireille BasselinStanley I Rapoport
Sep 26, 2008·Nitric Oxide : Biology and Chemistry·Ali Reza KarimollahAhmad Reza Dehpour
Nov 29, 2007·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Ho-Joo LeeRichard P Bazinet
Aug 31, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mehdi GhasemiAhmad Reza Dehpour
Jul 11, 2006·Nitric Oxide : Biology and Chemistry·Hamed SadeghipourAhmad Reza Dehpour
May 16, 2006·Biological Psychiatry·Renee N ErtleyJagadeesh S Rao
Mar 26, 2016·Expert Review of Neurotherapeutics·Liang PengAlexei Verkhratsky
Jun 27, 2009·Brain Research Reviews·Stanley I RapoportJagadeesh S Rao
Apr 14, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jagadeesh S RaoFrancesca Bosetti
Dec 20, 2007·Journal of Cardiovascular Pharmacology·Bahareh Rahimzadeh-RofouyiAhmad R Dehpour
Nov 25, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mireille BasselinStanley I Rapoport
Apr 7, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mireille BasselinStanley I Rapoport
Sep 17, 2009·Biochemical Society Transactions·Richard P Bazinet
Oct 22, 2008·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Chuck T ChenRichard P Bazinet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.